610302-03-9

Basic information

• Product Name: (3-HYDROXY-CYCLOHEXYL)-CARBAMIC ACID TERT-BUTYL ESTER
• Synonyms: TERT-BUTYL 3-HYDROXYCYCLOHEXYL CARBAMATE;(3-HYDROXY-CYCLOHEXYL)-CARBAMIC ACID TERT-BUTYL ESTER;3-N-BOC-AMINO-CYCLOHEXANOL;Carbamic acid, (3-hydroxycyclohexyl)-, 1,1-dimethylethyl ester (9CI);5-amino-2-methylpyridine-3-carboxylic acid;1-N-Boc aminocyclohexan-3-ol;cis-1-N-Boc-3-hydroxy-cyclohexylamine(racemic);trans-1-N-Boc-3-hydroxy-cyclohexylamine (racemic)
• CAS NO: 610302-03-9
• Molecular Formula: C₁₁H₂₁NO₃
• Molecular Weight: 215.29
• Product Categories: N-BOC;pharmacetical
• Mol File: 610302-03-9.mol

Chemical Properties

• Boiling Point: 337.7 °C at 760 mmHg
• Flash Point: 158 °C
• Appearance: /
• Density: 1.06
• Vapor Pressure: 7.02E-06mmHg at 25°C
• Refractive Index: 1.485
• Storage Temp.: 2-8°C
• PKA: 12.32±0.40(Predicted)
• CAS DataBase Reference: (3-HYDROXY-CYCLOHEXYL)-CARBAMIC ACID TERT-BUTYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: (3-HYDROXY-CYCLOHEXYL)-CARBAMIC ACID TERT-BUTYL ESTER(610302-03-9)
• EPA Substance Registry System: (3-HYDROXY-CYCLOHEXYL)-CARBAMIC ACID TERT-BUTYL ESTER(610302-03-9)

Safety Data

• Hazard Codes: Xn,N
• Statements: 22-50/53
• Safety Statements: 60-61
• Hazardous Substances Data: 610302-03-9(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
(3-Hydroxy-cyclohexyl)-carbamic acid tert-butyl ester is used as a reagent in organic synthesis for the preparation of various chemical compounds.
Used in Pharmaceutical Production:
In the pharmaceutical industry, (3-Hydroxy-cyclohexyl)-carbamic acid tert-butyl ester is used as a precursor in the production of drugs, contributing to the development of new medicinal compounds.
Used in Pesticide Production:
(3-Hydroxy-cyclohexyl)-carbamic acid tert-butyl ester is also utilized as a precursor in the manufacturing of pesticides, playing a role in the creation of effective pest control agents.
Used in Polymer Preparation:
In the polymer industry, (3-Hydroxy-cyclohexyl)-carbamic acid tert-butyl ester is used in the preparation of new polymers with potential applications in packaging, adhesives, and coatings, enhancing the properties of these materials.
Used in Anti-Tumor Research:
(3-Hydroxy-cyclohexyl)-carbamic acid tert-butyl ester has been investigated for its potential anti-tumor properties, indicating its possible use in the development of cancer treatment therapies.
Used in Anti-Inflammatory Research:
Additionally, this compound has shown promise in anti-inflammatory activities, suggesting its potential use in the treatment of inflammatory conditions.

InChI:InChI=1/C11H21NO3/c1-11(2,3)15-10(14)12-8-5-4-6-9(13)7-8/h8-9,13H,4-7H2,1-3H3,(H,12,14)

Upstream product

• 885280-38-6 (3-oxo-cyclohexyl)-carbamic acid tert-butyl ester 
• 24424-99-5 di-tert-butyl dicarbonate 
• 6850-39-1 3-aminocyclohexanol 

Downstream Products

• 1425253-99-1 C₁₁H₂₁NO₃ 
• 124555-43-7 (+/-)-cis-3-amino-cyclohexanol; hydrochloride 
• 885280-38-6 (3-oxo-cyclohexyl)-carbamic acid tert-butyl ester 
• 1383796-71-1 tert-butyl 3-(2-fluorophenoxy)cyclohexylcarbamate 

Relevant articles and documents

POLYFLUORINATED COMPOUNDS ACTING AS BRUTON TYROSINE KINASE INHIBITORS

Described herein is a novel series of multi-fluoro-substituted pyrazolopyrimidine compounds or salts thereof. These compounds are Bruton's tyrosine kinase (BTK) inhibitors. These compounds may possess better BTK inhibition selectivity and pharmacokinetic properties. Disclosed herein are the synthesis methods of these compounds. Disclosed herein are novel synthesis methods of the multi-fluoro-substituted benzophenone and substituted phenoxy benzene. Also disclosed are pharmaceutical compositions comprising the BTK inhibitors described herein. The present invention also relates to pharmaceutical formulations comprising the compounds described herein as active ingredients. The present invention also includes the therapeutic methods by administering the BTK inhibitors and their formulations to treat and inhibit autoimmune disease, hypersensitivity disease, inflammatory diseases and cancer.

TETRACYCLIC HETEROCYCLE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS

The present invention relates to Tetracyclic Heterocycle Compounds of Formula (I) and pharmaceutically acceptable salts or prodrug thereof, wherein n, X, Y, Z, R1, R2, and R3 are as defined herein. The present invention also relates to compositions comprising at least one Tetracyclic Heterocycle Compound, and methods of using the Tetracyclic Heterocycle Compounds for treating or preventing HIV infection in a subject.

SUBSTITUTED DIAMINOPYRIMIDYL COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH

Provided herein are diaminopyrimidyl Compounds having the following structures: wherein X, L, R1, and R2 are as defined herein, compositions comprising an effective amount of a Diaminopyrimidyl Compound, and methods for treating or preventing PKC-theta-mediated disorders, or a condition treatable or preventable by inhibition of a kinase, for example, PKC-theta.

SUBSTITUTED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF

The present disclosure relates to pyrimidine compounds of formula (I), their stereoisomers, tautomers, pharmaceutically acceptable salts, polymorphs, solvates, and hydrates thereof. The present disclosure also relates to process of preparation of these pyrimidine compounds, and to pharmaceutical compositions containing them. The compounds of the present disclosure are useful in the treatment, prevention or suppression of diseases and disorders mediated by epidermal growth factor receptor (EGFR) family kinases.

4 - [CYCLOALKYLOXY (HETERO) ARYLAMINO] THIENO [2, 3 - D] PYRIMIDINES HAVING MNKL/ MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS

The present invention relates to novel thienopyrimidine compounds of general formula (I), pharmaceutical compositions comprising these compounds and their therapeutic use for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof.